Loading...
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (15-Oct-26)
₹16.68-0.28%1D
Returns (Since Inception)
20.95%
Rated ★4.3+ on 
Fund Overview
Fund Size
₹927 Cr
Expense Ratio
1.13%
ISIN
INF03VN01886
Minimum SIP
₹500
Exit Load
No Charges
Inception Date
06 Feb 2024
About this fund
WhiteOak Capital Pharma and Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by WhiteOak Capital Mutual Fund. This fund has been in existence for 2 years, 8 months and 10 days, having been launched on 06-Feb-24.
As of 15-Oct-26, it has a Net Asset Value (NAV) of ₹16.68, Assets Under Management (AUM) of 926.55 Crores, and an expense ratio of 1.13%.
As of 15-Oct-26, it has a Net Asset Value (NAV) of ₹16.68, Assets Under Management (AUM) of 926.55 Crores, and an expense ratio of 1.13%.
- WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given a CAGR return of 20.95% since inception.
- The fund's asset allocation comprises around 98.95% in equities, 0.00% in debts, and 1.05% in cash & cash equivalents.
- You can start investing in WhiteOak Capital Pharma and Healthcare Fund Direct Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+15.83%
+10.74% (Cat Avg.)
Since Inception
+20.95%
— (Cat Avg.)
Portfolio Summaryas of 30th September 2026
| Equity | ₹916.82 Cr | 98.95% |
| Others | ₹9.73 Cr | 1.05% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Divi's Laboratories Ltd | Equity | ₹77.5 Cr | 8.36% |
| Cash Offset For Derivatives | Cash - General Offset | ₹-76.21 Cr | 8.22% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹65.86 Cr | 7.11% |
| Torrent Pharmaceuticals Ltd | Equity | ₹58 Cr | 6.26% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹51.47 Cr | 5.55% |
| Laurus Labs Ltd | Equity | ₹36.24 Cr | 3.91% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹34.78 Cr | 3.75% |
| Cipla Ltd | Equity | ₹34.07 Cr | 3.68% |
| Sai Life Sciences Ltd | Equity | ₹30.37 Cr | 3.28% |
| Ipca Laboratories Ltd | Equity | ₹26.65 Cr | 2.88% |
| Zydus Lifesciences Ltd | Equity | ₹26.07 Cr | 2.81% |
| Neuland Laboratories Ltd | Equity | ₹24.08 Cr | 2.60% |
| Dr. Lal PathLabs Ltd | Equity | ₹21.76 Cr | 2.35% |
| Corona Remedies Ltd | Equity | ₹21.64 Cr | 2.34% |
| Thyrocare Technologies Ltd | Equity | ₹21.07 Cr | 2.27% |
| Aurobindo Pharma Ltd | Equity | ₹19.39 Cr | 2.09% |
| Dr. Reddy's Laboratories Limited | Equity - Future | ₹19.18 Cr | 2.07% |
| Ajanta Pharma Ltd | Equity | ₹18.63 Cr | 2.01% |
| Future on Cipla Ltd | Equity - Future | ₹17.19 Cr | 1.86% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹17.11 Cr | 1.85% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹17.09 Cr | 1.84% |
| Shaily Engineering Plastics Ltd | Equity | ₹17.01 Cr | 1.84% |
| Global Health Ltd | Equity | ₹16.85 Cr | 1.82% |
| Narayana Hrudayalaya Ltd | Equity | ₹14.94 Cr | 1.61% |
| Anthem Biosciences Ltd | Equity | ₹14.56 Cr | 1.57% |
| Aurobindo Pharma Limited | Equity - Future | ₹14.48 Cr | 1.56% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹14.42 Cr | 1.56% |
| OneSource Specialty Pharma Ltd | Equity | ₹14.36 Cr | 1.55% |
| Acutaas Chemicals Ltd | Equity | ₹13.47 Cr | 1.45% |
| Navin Fluorine International Ltd | Equity | ₹13.09 Cr | 1.41% |
| Laurus Labs Limited | Equity - Future | ₹13.05 Cr | 1.41% |
| Fortis Healthcare Ltd | Equity | ₹12.62 Cr | 1.36% |
| Aarti Pharmalabs Ltd | Equity | ₹11.16 Cr | 1.20% |
| Mankind Pharma Ltd | Equity | ₹11.12 Cr | 1.20% |
| Procter & Gamble Health Ltd | Equity | ₹10.89 Cr | 1.18% |
| Molbio Diagnostics Ltd | Equity | ₹10.67 Cr | 1.15% |
| Rainbow Childrens Medicare Ltd | Equity | ₹10.63 Cr | 1.15% |
| Mankind Pharma Limited | Equity - Future | ₹10.38 Cr | 1.12% |
| Piramal Pharma Ltd | Equity | ₹9.82 Cr | 1.06% |
| Aether Industries Ltd | Equity | ₹9.72 Cr | 1.05% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹8.83 Cr | 0.95% |
| Gland Pharma Ltd | Equity | ₹8.62 Cr | 0.93% |
| Senores Pharmaceuticals Ltd | Equity | ₹7.44 Cr | 0.80% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹6.76 Cr | 0.73% |
| Supriya Lifescience Ltd | Equity | ₹6.43 Cr | 0.69% |
| Vimta Labs Ltd | Equity | ₹6.17 Cr | 0.67% |
| Innova Captab Ltd | Equity | ₹5.88 Cr | 0.63% |
| India (Republic of) | Bond - Short-term Government Bills | ₹5.57 Cr | 0.60% |
| India (Republic of) | Bond - Short-term Government Bills | ₹5.55 Cr | 0.60% |
| Nephrocare Health Services Ltd | Equity | ₹5.31 Cr | 0.57% |
| Net Receivables / (Payables) | Cash | ₹5.27 Cr | 0.57% |
| 91 Days Tbill (Md 10/12/2026) | Bond - Gov't/Treasury | ₹4.95 Cr | 0.53% |
| Manipal Health Enterprises Ltd | Equity | ₹4.8 Cr | 0.52% |
| India (Republic of) | Bond - Short-term Government Bills | ₹4.38 Cr | 0.47% |
| Sudeep Pharma Ltd | Equity | ₹4.23 Cr | 0.46% |
| Biocon Ltd | Equity | ₹3.9 Cr | 0.42% |
| Tatva Chintan Pharma Chem Ltd | Equity | ₹3.85 Cr | 0.42% |
| Orchid Pharma Ltd | Equity | ₹3.76 Cr | 0.41% |
| Zota Health Care Ltd | Equity | ₹3.73 Cr | 0.40% |
| India (Republic of) | Bond - Short-term Government Bills | ₹3.39 Cr | 0.37% |
| India (Republic of) | Bond - Short-term Government Bills | ₹2.98 Cr | 0.32% |
| Evonile Pharma Ltd | Equity | ₹2.25 Cr | 0.24% |
| Laxmi Dental Ltd | Equity | ₹2.12 Cr | 0.23% |
| Apollo Hospitals Enterprise Limited | Equity - Future | ₹1.93 Cr | 0.21% |
| India (Republic of) | Bond - Short-term Government Bills | ₹1.6 Cr | 0.17% |
| Bharat Parenterals Ltd | Equity | ₹0.9 Cr | 0.10% |
| India (Republic of) | Bond - Short-term Government Bills | ₹0.7 Cr | 0.08% |
| 12/11/2026 Maturing 364 DTB | Bond - Gov't/Treasury | ₹0.1 Cr | 0.01% |
Allocation By Market Cap (Equity)
Large Cap Stocks
31.02%
Mid Cap Stocks
21.72%
Small Cap Stocks
38.18%
Allocation By Credit Quality (Debt)
AAA
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹783.48 Cr | 84.56% |
| Basic Materials | ₹57.13 Cr | 6.17% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
16.41%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.81
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.37
Higher the better
Fund Managers
Piyush Baranwal
Since February 2024
Ramesh Mantri
Since February 2024
TA
Trupti Agrawal
Since May 2025
DP
Dheeresh Pathak
Since February 2024
AA
Ashish Agrawal
Since January 2025
Additional Scheme Detailsas of 30th September 2026
ISIN INF03VN01886 | Expense Ratio 1.13% | Exit Load No Charges | Fund Size ₹927 Cr | Age 2 years 8 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
About the AMC
WhiteOak Capital Mutual Fund
Total AUM
₹46,592 Cr
Address
1&2 Senapati Bapat Marg, Elphinstone Road (West) Mumbai Mumbai City, Mumbai
Other Funds by WhiteOak Capital Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Take control of your wealth
Related Articles
Still got questions?
We're here to help.
What is the current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
The NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth, as of 15-Oct-2026, is ₹16.68.
What is the portfolio composition of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
The fund's allocation of assets is distributed as 98.95% in equities, 0.00% in bonds, and 1.05% in cash and cash equivalents.
Who manages the WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
The fund managers responsible for WhiteOak Capital Pharma and Healthcare Fund Direct Growth are:-
- Piyush Baranwal
- Ramesh Mantri
- Trupti Agrawal
- Dheeresh Pathak
- Ashish Agrawal
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
©2021-2026 Dezerv. All Rights Reserved
Dezerv Investments Pvt. Ltd. is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Dezerv Investments Pvt. Ltd. is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
